title: [Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients].
abstract: Tumor cell metabolism is characterized by a high rate of aerobic glycolysis. The metabolic differences require changes in glycolytic enzyme activities and isoenzyme patterns. The inactive form of the M2 pyruvate kinase (Tu M2-PK) is specifically expressed in tumor cells and has been detected immunohistochemically in tumor tissue but also in peripheral blood of patients with different malignant tumors. In this study, Tu M2-PK in the plasma of patients with renal cell carcinoma (RCC) was compared with healthy volunteers. Tu M2-PK was quantified with a commercially available enzyme linked immunosorbent assay (ELISA) kit. Using the ELISA kit, plasma probes of 57 healthy individuals were compared to 63 patients with RCC (51 patients with non-metastatic RCC, 12 patients with metastatic RCC). Statistical analysis was performed with the non-parametric ANOVA test according to Kruskal-Wallis. In patients with renal cell carcinoma, Tu M2-PK was significantly higher than in healthy volunteers. For organ-defined, non-metastatic tumors, sensitivity was only 27.5%, if the 95% reference values of the control group were used for discrimination. The differences were more pronounced in patients with metastatic disease. Tu M2-PK was significantly enhanced compared to healthy controls, but also to the group with non-metastatic disease, the sensitivity was 66.7%. Our data show that Tu M2-PK has no impact as an unspecific marker for the diagnosis of renal cell carcinoma. This is especially relevant to organ-defined, non-metastatic RCC. In advanced metastatic disease, a potential importance as a parameter for treatment control in palliative therapeutic approaches can be assumed, and warrants further investigations.
authors.affiliation: Klinik und Poliklinik für Urologie, Campus Mitte, Universitätsklinikum Charité, Humboldt-Universität zu Berlin. jan.roigas@charite.de
authors.forename: J
authors.initials: J
authors.lastname: Roigas
authors.forename: G
authors.initials: G
authors.lastname: Schulze
authors.forename: S
authors.initials: S
authors.lastname: Raytarowski
authors.forename: K
authors.initials: K
authors.lastname: Jung
authors.forename: D
authors.initials: D
authors.lastname: Schnorr
authors.forename: S A
authors.initials: SA
authors.lastname: Loening
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D002292:Carcinoma, Renal Cell / Q000175:diagnosis* / Q000201:enzymology / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000201:enzymology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011770:Pyruvate Kinase / Q000097:blood*
chemical_list: D014408:Biomarkers, Tumor; D011770:Pyruvate Kinase